glp 1 drugs and bipolar disorder GLP-1 receptor agonists in addiction affective disorders: Implications for dual disorders New research links genetic activation

Used as a research tool to study cellular senescence

Endocrinology 124, 167174

reliable contraception should be in place, and any plans to conceive should be discussed with a clinician before starting or stopping treatment If you experience any of the following whilst using retatrutide or any weight-loss agent, seek prompt medical attention: Severe or persistent nausea, vomiting, or abdominal pain particularly pain radiating to the back, which may indicate pancreatitis Right upper quadrant pain, jaundice, or fever, which may suggest gallbladder disease Persistent vomiting with reduced urine output or signs of dehydration Signs of low blood sugar (shakiness, sweating, confusion, dizziness) Rapid or irregular heartbeat Unexplained muscle weakness or pain Rash, swelling of the face or throat, or difficulty breathing, which may indicate a serious allergic reaction Retatrutide has no UK marketing authorisation

Int J Cancer 125 (8): 1868-75, 2009